School of Pharmacy, Guangdong Pharmaceutical University.
Department of Respiratory, Guangdong Provincial People's Hospital.
Biol Pharm Bull. 2021 Feb 1;44(2):169-180. doi: 10.1248/bpb.b20-00504. Epub 2020 Nov 25.
Chronic stress-induced brain injury (CSBI) is the organic damage of brain tissue caused by long-term psychological and environmental stress. However, there is no effective drug for the treatment of CSBI. The present study aimed to investigate possible mechanisms of CSBI and to explore related therapeutic targets. A rat model of CSBI was established by combining chronic restraint and cold water immersion. Our CSBI model was validated via Nissl staining, Western blotting, and behavioral tests. RNA sequencing (RNA-seq) was used to identify differentially expressed genes (DEGs) within brain tissue during CSBI. Both Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) analyses were performed to determine signaling pathways associated with CSBI-induced DEGs. Agonists/antagonists were used to validate the pharmacodynamics of potential therapeutic targets. A combination of chronic restraint and cold water immersion successfully induced a rat model of CSBI, as indicated by various markers of brain injury and cell apoptosis that were verified via Nissl staining, Western blotting, and behavioral tests. RNA-seq analysis identified 1131 DEGs in CSBI rats. Of these DEGs, 553 genes were up-regulated and 778 genes were down-regulated. GO and KEGG pathway analyses revealed that significant DEGs were predominantly related to membrane-bound ion channels, among which the potassium channel function was found to be significantly affected. Pharmacological experiments revealed that retigabine, a voltage-gated potassium channel opener, demonstrated a protective effect in CSBI rats. Taken together, our findings suggest that potassium channel function is disrupted in CSBI, and that potassium channel regulators may function as anti-CSBI drugs.
慢性应激诱导性脑损伤(CSBI)是由长期心理和环境应激引起的脑组织器质性损伤。然而,目前尚无治疗 CSBI 的有效药物。本研究旨在探讨 CSBI 的可能机制,并探索相关治疗靶点。通过结合慢性束缚和冷水浸泡建立 CSBI 大鼠模型。通过尼氏染色、Western blot 和行为学测试验证我们的 CSBI 模型。采用 RNA 测序(RNA-seq)鉴定 CSBI 期间脑组织中差异表达基因(DEGs)。对 CSBI 诱导的 DEGs 进行京都基因与基因组百科全书(KEGG)和基因本体论(GO)分析,以确定与 CSBI 相关的信号通路。使用激动剂/拮抗剂验证潜在治疗靶点的药效学。慢性束缚和冷水浸泡的联合成功诱导了 CSBI 大鼠模型,这通过尼氏染色、Western blot 和行为学测试验证的脑损伤和细胞凋亡的各种标志物来表明。RNA-seq 分析鉴定出 CSBI 大鼠中有 1131 个 DEGs。这些 DEGs 中,有 553 个基因上调,778 个基因下调。GO 和 KEGG 通路分析表明,显著 DEGs 主要与膜结合离子通道相关,其中钾通道功能受到明显影响。药理实验表明,电压门控钾通道开放剂 retigabine 在 CSBI 大鼠中具有保护作用。总之,我们的研究结果表明,钾通道功能在 CSBI 中被破坏,钾通道调节剂可能作为抗 CSBI 药物发挥作用。